


What is Claimed is:

1. A compound of the formula :



5 wherein

R₁ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl alkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenylalkyl, aryl, arylalkyl, heterocyclic, heterocyclylalkyl, heteroaryl, or heteroarylalkyl moiety, all of which moieties may be optionally substituted;

10 R₂ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, heterocyclylC₁₋₁₀ alkyl moiety, all of which moieties may be optionally substituted;

X is a bond, oxygen, nitrogen or sulfur;

15 R₃ is an optionally substituted aryl or optionally substituted heteroaryl moiety;

Y is carbon or nitrogen;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein R₁ is an optionally substituted aryl, arylalkyl, heterocyclylalkyl, aminoalkyl, or mono- or di-substituted aminoalkyl.

3. The compound according to Claim 2 wherein the aryl or arylalkyl is optionally substituted one or more times, independently by halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.

25

4. The compound according to Claim 3 wherein the aryl is phenyl substituted one or more times with halogen.

5. The compound according to Claim 1 wherein R₂ is an optionally substituted alkyl, or heteroarylalkyl.


30

6. The compound according to Claim 5 wherein the alkyl is an optionally substituted by hydroxy, C(O)OR₆, NR₄R₁₄.
7. The compound according to Claim 1 wherein X is a bond.
8. The compound according to Claim 7 wherein R₃ is an optionally substituted aryl.
9. The compound according to Claim 8 wherein the aryl is optionally substituted 1 to 3 times independently by halogen, alkyl, amino, or hydroxy.
10. The compound according to Claim 1 which is:
N-1-(2,6-Difluorophenyl)-N-[2-(4-fluoro-2-methylphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]urea, or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising an effective amount of a compound according to any one of Claims 1 to 10 and a pharmaceutically acceptable carrier or diluent.
12. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to any one of Claims 1 to 10.
13. The method according to Claim 12 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac, brain and renal reperfusion injury, thrombosis, glomerulonephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenerative disease, muscle degeneration, diabetic retinopathy, macular

degeneration, tumor growth and metastasis, angiogenic disease, rhinovirus infection, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis.

14. A compound of the formula :

5



wherein

R₁ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl alkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenylalkyl, aryl, arylalkyl, heterocyclic,

10 heterocyclicalkyl, heteroaryl, or heteroarylalkyl moiety, all of which moieties may be optionally substituted;

R₂ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, heterocyclicC₁₋₁₀ alkyl moiety, all of which moieties may be

15 optionally substituted;

X is a bond, oxygen, nitrogen or sulfur;

R₃ is an optionally substituted aryl or optionally substituted heteroaryl moiety;

Y is carbon or nitrogen;

or a pharmaceutically acceptable salt thereof.

20

15. The compound according to Claim 14 wherein R₁ is an optionally substituted aryl, arylalkyl, heterocyclicalkyl, aminoalkyl, or mono- or di-substituted aminoalkyl.

16. The compound according to Claim 15 wherein the aryl or arylalkyl is optionally substituted one or more times, independently by halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.

25

17. The compound according to Claim 16 wherein the aryl is phenyl substituted one or more times with halogen.

30

18. The compound according to Claim 14 wherein R₂ is an optionally substituted alkyl, or heteroarylalkyl.
19. The compound according to Claim 18 wherein the alkyl is an optionally substituted by hydroxy, C(O)OR₆, NR₄R₁₄.
20. The compound according to Claim 14 wherein X is a bond.
21. The compound according to Claim 20 wherein R₃ is an optionally substituted aryl.
22. The compound according to Claim 21 wherein the aryl is optionally substituted 1 to 3 times independently by halogen, alkyl, amino, or hydroxy.
23. A pharmaceutical composition comprising an effective amount of a compound according to any one of Claims 14 to 22 and a pharmaceutically acceptable carrier or diluent.
24. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to any one of Claims 14 to 22.
25. The method according to Claim 24 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac, brain and renal reperfusion injury, thrombosis, glomerulonephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenerative disease, muscle degeneration, diabetic retinopathy, macular

degeneration, tumor growth and metastasis, angiogenic disease, rhinovirus infection, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis.

26. A process of making a compound of Formula (I) according to Claim 1 which
5 comprises reacting a compound of Formula (II), according to Claim 14 with tri-phosgene, phosgene, diphenyl carbonate or other activated carbonate equivalents, and ammonia to yield a compound of Formula (I).